Clinical Trial Update: Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical study of regorafenib and nivolumab plus chemotherapy for gastric and gastroesophageal junction adenocarcinoma (and esophageal adenoca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Chemotherapy (chemotherapy)
• OPDIVO (nivolumab)
• Stivarga (regorafenib)

Snippet

Sponsor: National Cancer Center Hospital East | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED